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Therapeutic monoclonal antibodies against the epidermal growth factor receptor 
(EGFR) act by inhibiting EGFR downstream signaling and by eliciting a natural killer (NK) 
cell-mediated antitumor response. The IgG1 mAb cetuximab has been used for treat-
ment of RASwt metastatic colorectal cancer (mCRC) patients, showing limited efficacy. 
In the present study, we address the potential of adoptive NK cell therapy to overcome 
these limitations investigating two allogeneic NK cell products, i.e., allogeneic activated 
peripheral blood NK cells (A-PBNK) and umbilical cord blood stem cell-derived NK 
cells (UCB-NK). While cetuximab monotherapy was not effective against EGFR− RASwt, 
EGFR+ RASmut, and EGFR+ BRAFmut cells, A-PBNK were able to initiate lysis of EGFR+ 
colon cancer cells irrespective of RAS or BRAF status. Cytotoxic effects of A-PBNK (but 
not UCB-NK) were further potentiated significantly by coating EGFR+ colon cancer cells 
with cetuximab. Of note, a significantly higher cytotoxicity was induced by UCB-NK in 
EGFR−RASwt (42 ± 8 versus 67 ± 7%), EGFR+ RASmut (20 ± 2 versus 37 ± 6%), and 
EGFR+ BRAFmut (23 ±  3 versus 43 ±  7%) colon cancer cells compared to A-PBNK 
and equaled the cytotoxic efficacy of the combination of A-PBNK and cetuximab. The 
antitumor efficacy of UCB-NK cells against cetuximab-resistant human EGFR+ RASmut 
colon cancer cells was further confirmed in an in vivo preclinical mouse model where 
UCB-NK showed enhanced antitumor cytotoxicity against colon cancer independent 
of EGFR and RAS status. As UCB-NK have been proven safe in a recently conducted 
phase I clinical trial in acute myeloid leukemia, a fast translation into clinical proof of 
concept for mCRC could be considered.
Keywords: egFr, ras mutation, cetuximab, metastatic colorectal cancer, a-PBnK, UcB-nK, allogeneic nK cell 
immunotherapy
inTrODUcTiOn
Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths in the world (1). Despite 
substantial advances in the treatment of metastatic CRC (mCRC) over the last decades that have 
contributed to better survival rates (2, 3), the disease is still frequently fatal. Monoclonal antibodies 
(mAbs) targeting the epidermal growth factor receptor (EGFR) pathway, such as panitumumab 
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and cetuximab, are approved for the treatment of patients with 
advanced CRC either in combination with chemotherapy or, as 
monotherapy, in chemorefractory conditions (4). Cetuximab 
(CET) and panitumumab block the interaction between EGFR 
and its ligands, thus inhibiting the downstream RAS-signaling 
cascade and tyrosine kinase activation (5). However, mutations in 
tumor suppressor genes and proto-oncogenes in EGFR signaling 
pathways, such as in RAS, BRAF, and PIK3CA, are common in 
patients with CRC. These mutations represent a poor prognostic 
marker and render anti-EGFR mAbs ineffective, leaving 42% of 
the chemorefractory mCRC population without this standard 
treatment option (6, 7).
Besides the blockade of the EGFR–ligand interaction on tumor 
cells, therapeutic mAbs can also interact with natural killer (NK) 
cells triggering antibody-dependent cell-mediated cytotoxicity 
(ADCC) (8–10), and this can translate into superior antitumor 
effects (11). Two NK cell subsets can be identified based on the 
expression of CD16, the low affinity FcγRIIIa receptor. The major-
ity of NK cells are CD56dimCD16+ and play an active role in NK 
cell cytotoxicity and are capable of performing ADCC upon IgG1 
engagement via CD16, whereas CD56brightCD16− NK cells are 
mainly immune regulatory in function, secreting cytokines, and 
are less cytotoxic than CD56dim cells (12). NK cell functions are 
tightly regulated by a delicate balance between activating recep-
tors (like the natural cytotoxicity receptors NKp46, NKp30, and 
NKp44, or C-type lectin-like receptor NKG2D) (13) and major 
histocompatibility complex (MHC) class I binding inhibitory 
receptors, including killer cell immunoglobulin-like receptors 
(KIRs), LIR1/ILT2, and NKG2A/CD94 (14). The importance of 
NK cells in controlling tumors has been extensively demonstrated 
since their identification 40 years ago (15–17).
Several studies have shown a dysfunctional phenotype and 
poor infiltration of NK cells in the CRC tissue from early stages 
on, together with an immunosuppressive tumor microenviron-
ment (18, 19). Hence, various strategies, e.g., using cytokines 
or therapeutic ADCC enhancing mAbs, have been explored to 
increase NK cell numbers and function and to enhance their traf-
ficking to tumor sites (20). Another approach entails the adop-
tive transfer of in  vitro manipulated and expanded autologous 
or allogeneic NK cells. Autologous NK cells so far have failed 
to demonstrate significant therapeutic benefits in solid tumors 
(21–23). Therefore, the focus has shifted to the development 
of allogeneic NK cells as a potential adoptive cell therapy for 
treatment in solid tumors. Previously, we demonstrated that the 
combination of allogeneic activated peripheral blood NK cells 
(A-PBNK) and CET can effectively target RAS mutant (RASmut) 
CRC tumors (24).
Here, we compared two feeder cell-free allogeneic NK cell 
products, i.e., A-PBNK and umbilical cord blood stem-cell derived 
NK cells (UCB-NK), alone or in combination with cetuximab for 
antitumor effects against RASmut CRC.
MaTerials anD MeThODs
cell lines
Cell lines A431 (epidermoid carcinoma), COLO320, SW480, and 
HT-29 (colon carcinoma) were obtained from American Type 
Culture Collection and cultured in Dulbecco’s modified medium 
(DMEM; Invitrogen, Carlsbad, CA, USA) containing 100 U/ml 
penicillin, 100  µg/ml streptomycin, and 10% fetal calf serum 
(FCS; Integro, Zaandam, The Netherlands). Cell cultures were 
passaged every 5 days and maintained in a 37°C, 95% humidity, 
5% CO2 incubator.
PBnK isolation and activation
Peripheral blood mononuclear cells (PBMCs) were isolated 
from the heparinized blood of healthy donors (six males, four 
females, age range = 56–64 years and CRC patients (eight males, 
two females, age range =  66–74  years) after written informed 
consent and according to protocols approved by the institutional 
review board of VU University Medical Center, Amsterdam 
(NCT01792934). Blood samples were collected at baseline and 
after the first cycle of first-line palliative chemotherapy consisting 
of oral capecitabine (1,000 mg/m2, bid, days 1–14), i.v. oxaliplatin 
(130 mg/m2, day 1), and i.v. bevacizumab (7.5 mg/kg, day 1, in 
4/10 mCRC patients). PBMCs were isolated using Lymphoprep™ 
(STEMCELL Technologies, Cologne, Germany) density gradient 
centrifugation. CD56+ NK cells were isolated from PBMC using 
a MACS Human NK cell isolation kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s instruc-
tions. PBNK cells purity and viability were checked using CD3 
VioBlue, CD56 APC Vio 770, and CD16 APC (Miltenyi Biotech) 
and 7-AAD (Sigma Aldrich, Zwijndrecht, The Netherlands). 
Isolated PBNK cells were activated overnight with 1,000 U/ml 
IL-2 (Proleukin®; Chiron, München, Germany) and 10  ng/ml 
IL-15 (CellGenix) for use in cytotoxicity assays. The parameters 
compared before and after stimulation with cytokines were NK 
purity (87 ±  5 versus 84 ±  2%), NK CD16+, (92 ±  12 versus 
88 ± 8%) and NK viability (89 ± 5 versus 84 ± 8%), respectively.
Flow cytometry
The antibody staining mix for the assessment of NK cell func-
tionality consisted of CD45 VioGreen, CD14 VioBlue, CD19 
VioBlue, and SYTOX® Blue, together with CD3 PerCP-Vio 700 
and TCRγδ PerCP-Vio700 to exclude dead cells, debris, and 
non-NK populations from PBMCs. NK cells were identified by 
the expression of CD45+CD3−CD56+ cells, and further character-
ized for NK functionality by plotting against CD16 APC, CD25 
VioBrightFITC, CD107a PE, and NKp44 PE-Vio770 and for NK 
cell phenotype by plotting against NKG2A PE-Vio770, NKG2C 
PE, NKG2D PerCP-Cy5.5, and PanKIR2D FITC. All antibodies 
were supplied by Miltenyi Biotec except SYTOX® Blue (Thermo 
Fisher Scientific, Berlin, Germany).
UcB-nK cultures
Allogeneic NK cells (UCB-NK) were generated from cryopre-
served umbilical cord blood (UCB) hematopoietic stem cells as 
previously described (25). CD34+ UCB cells from six UCB-donors 
were plated (4 × 105/ml) into 12-well tissue culture plates (Corning 
Incorporated, Corning, New York, NY, USA) in Glycostem Basal 
Growth Medium (GBGM®) (Clear Cell Technologies, Beernem, 
Belgium) supplemented with 10% human serum (HS; Sanquin 
Bloodbank, Amsterdam, The Netherlands), 25  ng/ml of SCF, 
Flt-3L, TPO, and IL-7 (CellGenix, Freiburg, Germany). In the 
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expansion phase II, from day 9 to day 14, TPO was replaced with 
20 ng/ml IL-15 (CellGenix). During the first 14 days of culture, 
low molecular weight heparin (Clivarin®; Abbott, Wiesbaden, 
Germany) in a final concentration of 20 µg/ml and a low-dose 
cytokine cocktail consisting of 10 pg/ml GM-CSF (Neupogen), 
250 pg/ml G-CSF and 50 pg/ml IL-6 (CellGenix) were added to 
the expansion cultures. Cells were refreshed with new medium 
twice a week and maintained at 37°C, 5% CO2. On day 14, the 
NK cell differentiation process was initiated by addition of NK 
cell differentiation medium consisting of the same basal medium 
with 2% HS but with high-dose cytokine cocktail consisting 
of 20  ng/ml of IL-7, SCF, IL-15 (CellGenix), and 1,000  U/ml 
IL-2 (Proleukin®; Chiron, München, Germany). Cultures were 
refreshed every 2–3 days and maintained till day 42. Five UCB-NK 
cultures were used for cytotoxicity assays and one UCB-NK cul-
ture for in vivo studies (both with a CD56+ cell purity of >95%). 
UCB-NK CD16 levels in matured UCB-NK cells were monitored 
using an antibody mix of human CD45VioGreen (1:11), CD56 
APC-Vio770 (1:11), and CD16 APC (1:11). Similarly, UCB-NK 
CD16 expression in BRGS mice was monitored using an antibody 
mix of BV650 anti-mouse CD45 (clone 30-F11), Alexa Fluor® 700 
anti-human CD45 (clone HI30), PE-CF594 anti-human CD56 
(clone B159), all from BD, and APC-Vio770 anti-human CD56 
(clone REA196) and APC CD16 (clone REA423) both from 
Miltenyi Biotec.
nK cell cytotoxicity assays
Flow cytometry was used for the readout of cytotoxicity assays. 
Target cells (COLO320, SW480, and HT-29) were labeled 
with 5  µM pacific blue succinimidyl ester (PBSE; Molecular 
Probes Europe, Leiden, The Netherlands) at a concentration of 
1 × 107 cells/ml for 10 min at 37°C. The reaction was terminated 
by adding an equal volume of FCS, followed by incubation 
at room temperature for 5  min after which stained cells were 
washed twice and suspended in DMEM +  10% FCS to a final 
concentration of 5 ×  105/ml. Overnight activated PBNK cells 
and UCB-NK cells were washed with PBS and suspended in 
GBGM + 2% FCS to a final concentration of 5 × 105/ml. Target 
cells were cocultured with effector cells at an E:T ratio of 1:1 in a 
total volume of 250 µl in 96-well flat-bottom plates (5 × 104 targets 
in 100 µl of DMEM + 10% FCS incubated with 5 × 104 effectors 
in 100 µl of GBGM + 2% FCS, further supplemented with 25 µl 
of GBGM + 2% FCS and DMEM + 10% FCS medium). NK cells 
and target cells alone were plated out in triplicate as negative 
controls. Target cells were coated with 5 µg/ml cetuximab (Merck, 
Darmstadt, Germany) for 1 h at 4°C. To measure degranulation of 
NK cells, anti-CD107a PE (Miltenyi Biotech) was added in 1:20 
dilution at the beginning of the assay. After incubation for 4 h 
at 37°C, cells were harvested and stained with CD56 APC Vio 
770 (1:25) and CD16 APC (1:25) (Miltenyi Biotech) and 7-AAD 
(1:500) (Sigma Aldrich). Degranulation of NK cells was measured 
by detecting cell surface expression of CD107a.
In Vivo studies
The EGFR+RASmut SW480 cell line and EGFR+++RASwt A431 
cell line were stably transduced with Gaussia Luciferase (Gluc) 
for in  vivo studies. Lentiviral (LV) supernatant of Cerulean 
Fluorescent Protein (CFP)-positive Gluc virus (LV-CFP-Gluc) 
was kindly provided by Dr. Tom Würdinger (26). SW480 and 
A431 cells with Gluc expression of 95% were used for mouse 
studies.
Immunodeficient BRGS mice (BALB/c Rag2tm1Fwa Il2rgtm1Cgn 
SirpaNOD) were used in this study. Twenty-four adult mice (male, 
8 weeks old) received an intravenous (i.v.) tail vein injection with 
0.5 × 106 SW480 Gluc cells at day 0 and were randomized into 
four groups. Group A only received SW480 cells, group B received 
SW480 in combination with cetuximab intraperitoneally (i.p., 
0.5 mg, days 1, 4, and 7), group C received SW480 in combination 
with UCB-NK i.v. (1 × 107, days 1, 4, and 7), and group D received 
SW480 cells in combination with UCB-NK i.v. (1 × 107, days 1, 4, 
and 7) and cetuximab i.p. (0.5 mg, days 1, 4, and 7). Groups C and 
D received i.p. 0.5 µg IL-15 + 7.5 µg IL-15Rα every 2–3 days from 
day 0 till day 14. Further, three adult mice received i.v. tail vein 
injection of 0.5 × 106 A431 Gluc cells at day 0 and were treated 
with 0.5  mg cetuximab (i.p., 0.5  mg, days 1, 4, and 7), which 
were used as a cetuximab efficacy control. Treatment effects were 
monitored using blood Gluc levels and bioluminescence imaging 
(BLI). All manipulations of BRGS mice were performed under 
laminar flow conditions.
Blood gluc Quantification In Vitro
Secreted Gluc was measured according to a protocol described 
previously (27). A total of 10 µl of blood was collected by capillar-
ity into EDTA containing Microvette® CB tubes. Blood samples 
were distributed in 96-well black plates then mixed with 100 µl 
of 100 mM Gluc substrate native coelenterazine in PBS (P.J.K. 
GmbH, Kleinblittersdorf, Germany), and 5 min later, light emis-
sion was quantified. Blood that was withdrawn before tumor 
inoculation served to determine a baseline value. Measurements 
were done twice a week until day 35. Gluc activity was measured 
using IVIS spectrum luminescence detector (PerkinElmer, 
Villebon-sur-Yvette, France). Data obtained were quantified 
using Living Image 4.0 software (PerkinElmer, Villebon-sur-
Yvette, France).
Bli In Vivo
Mice were anesthetized using isofluorane gas in an induction 
chamber at a gas flow of 2.5 pm. Retro-orbital injection of coelen-
terazine (4 mg/kg body weight) was administered and mice were 
placed in the anesthesia manifold inside the imaging chamber 
and imaged within 5 min following substrate injection. Mice were 
placed into the light chamber and overlay images were collected 
for a period of 15  min using IVIS spectrum in  vivo imaging 
system (PerkinElmer, Villebon-sur-Yvette, France). Images were 
then analyzed using Living Image 4.0 software (PerkinElmer, 
Villebon-sur-Yvette, France).
ethics statement
Animals were housed in isolators under pathogen-free condi-
tions with humane care and anesthesia was performed using 
inhalational isoflurane anesthesia to minimize suffering. 
Experiments were approved by the Institut Pasteur’s ethical 
committee for animal use in research, Comité d’étique en expéri-
mentation animale (CETEA) #89, protocol reference # 2007–006 
FigUre 1 | low prevalence and functionally impaired natural killer (nK) cells in colorectal cancer (crc) patients. (a) Frequency of NK cells within 
peripheral blood mononuclear cells from healthy controls and from metastatic CRC (mCRC) patients at baseline and after the first cycle of chemotherapy. (B) NK cell 
degranulation in healthy controls and mCRC patients after a 4-h coculture of resting NK cells with A431 cells in the presence (open symbols) or absence (closed 
symbols) of cetuximab at an E:T ratio of 1:1. (c) Expression levels of resting NK cell CD16 and (D) NKp44 in healthy controls and in mCRC patients before and after 
one cycle of chemotherapy. Data represent mean ± SEM from 10 mCRC patients and 10 age- and sex-matched healthy controls. *P < 0.05, **P < 0.01, 
***P < 0.005, calculated with one-way ANOVA, multiple comparison between column means.
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and validated by the French Ministry of Education and Research 
(Reference # 02162.01).
statistical analysis
Data were analyzed using GraphPad Prism version 6 (GraphPad 
Software, San Diego, CA). Differences between conditions were 
determined using one-way ANOVA or two-way ANOVA with 
multiple comparisons between column means, unpaired t test and 
log-rank (Mantel–Cox) test as deemed appropriate. A P-value of 
<0.05 was considered statistically significant.
resUlTs
highly Dysfunctional nK cells in crc 
Patients
Flow cytometry was used to determine the frequency, phenotype, 
and functionality of NK cells in PBMC of healthy volunteers 
(n = 10, age range 56–64 years, 6 males/4 females) and patients with 
metastatic CRC (n = 10, age range 66–74 years, 8 males/2 females) 
before and after the first cycle of first-line palliative chemotherapy 
consisting of oral capecitabine (1,000 mg/m2, bid, days 1–14), i.v. 
oxaliplatin (130  mg/m2, day 1), and i.v. bevacizumab (7.5  mg/
kg, day 1, in 4/10 mCRC patients). As illustrated in Figure 1A, 
mCRC patients harbored on average a 20% lower percentage of 
CD3−CD56+NK cells in the total CD45+ lymphocyte population 
as compared to healthy controls (P < 0.05). These lower NK rates, 
which are in line with a previous report in CRC (28), further 
declined after the first cycle of chemotherapy (P < 0.01).
We next evaluated whether this quantitative NK cell defect was 
also accompanied by functional defects in the NK cell population. 
For this purpose, the ability of NK cells from healthy volunteers 
and mCRC patients to induce both natural cytotoxicity and medi-
ate ADCC of the epidermoid carcinoma cell line A431 (MHC-Ilow, 
EGFRhigh, KRASwt) was assessed. For ADCC, tumor target cells 
were coated with cetuximab before the addition of NK cells. It 
was evident that the cytotoxic potential of NK cells from mCRC 
patients, as reflected by degranulation (i.e., CD107a surface 
expression), was highly impaired both before chemotherapy and 
after the first cycle of chemotherapy. Though NK cells of mCRC 
patients were capable of ADCC, as evidenced by significant 
increases in degranulation when target cells were coated with 
cetuximab (P <  0.05), levels were still low compared to those 
observed in healthy volunteers (Figure  1B). Of note, although 
the NK cells of healthy volunteers and mCRC patients expressed 
similar levels of CD16 (Figure  1C), this did not translate into 
comparable levels of ADCC. NKp44 expression, known to reflect 
the activation status of NK cells, was similar between the HD and 
mCRC groups used in NK cytotoxicity experiments (Figure 1D). 
Furthermore, no significant differences were observed in expres-
sion levels of NK activating (NKG2D, NKG2C) and NK inhibiting 
FigUre 2 | Ex vivo cytotoxic efficacy of a-PBnK and UcB-nK cells against colorectal cancer (crc) cells. CRC cell lines COLO320 (EGFR−, RASwt), 
SW480 (EGFR+, RASmut), and HT-29 (EGFR+, RASwt, BRAFmut) were subjected to natural killer (NK) killing using two allogeneic NK cell products, i.e., A-PBNK and 
UCB-NK cells. 7-AAD (a,B,c) and CD107a (D,e,F) were measured after a 4-h coculture of A-PBNK and UCB-NK cells with CRC targets in the presence or 
absence of cetuximab at an E:T ratio of 1:1. Experiments were carried out in triplicate. Bars represent mean ± SEM, n = 5. *P < 0.05 and **P < 0.01, calculated 
with two-way ANOVA, multiple comparison between column means.
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(NKG2A, KIR2D) receptors between healthy controls and CRC 
patients (Figure S1 in Supplementary Material).
enhanced In Vitro cytotoxicity of colon 
cancer cells Mediated by UcB-nK cells
In order to explore novel therapies to replace dysfunctional NK 
cells in patients with advanced CRC, we tested two different sources 
of allogeneic NK cell products (A-PBNK and UCB-NK) that 
could eventually be used for adoptive transfer strategies. We next 
compared the activity of A-PBNK cells (age range 22–37 years) 
and UCB-NK cells using a flow based NK cell cytotoxicity assay 
based on detection of 7-AAD accumulation in tumor cells. Three 
different cell lines of colon cancer origin were compared, i.e., 
COLO320 (EGFR− RASwt), SW480 (EGFR+ RASmut), and HT-29 
(EGFR+ RASwt BRAFmut). As expected, addition of cetuximab to 
EGFR− RASwt COLO320 cells did not result in increased kill-
ing. Of interest, lysis was consistently and significantly higher 
(P <  0.01) using UCB-NK compared to A-PBNK. As reported 
previously, the combination of cetuximab and A-PBNK resulted 
in increased killing of EGFR+RASmut SW480 and EGFR+ BRAFmut 
HT-29 via ADCC (24). CD16 was expressed by 88 ± 8% (n = 5) 
of A-PBNK after overnight stimulation with cytokines and by 
7 ± 2% (n = 5) of UCB-NK cells at the end of the 35-day culture 
period. No added effect of cetuximab was observed when using 
UCB-NK cells, which is possibly related to their lower in vitro 
CD16 levels (29). Of note, tumor cell lysis induced by UCB-NK 
cells was comparable to that observed with the combination of 
A-PBNK and cetuximab (Figures 2A,B,C). Measurements of NK 
cell degranulation reflected equivalent trends observed for tumor 
cell lysis (Figures  2D,E,F). These results show that UCB-NK 
cells have superior cytotoxic efficacy over A-PBNK cells against 
cetuximab-resistant colon cancer cells in vitro.
UcB-nK cells inhibit In Vivo Tumor 
growth and increase survival
To address whether UCB-NK cells exhibit similar antitumor 
efficacy in  vivo, we transferred Gluc transduced SW480 cells 
to immunodeficient mice (BRGS; see Materials and Methods). 
SW480 cells are EGFR+RASmut and cetuximab monotherapy 
resistant. Mice were divided into four groups of six mice per 
group: SW480 only (group A), SW480 + cetuximab (group B), 
SW480 + UCB-NK (group C), and SW480 + UCB-NK + cetuxi-
mab (group D). Gaussia luciferase activity in whole blood was 
measured every 3 days to monitor the tumor burden (Figure S2 
in Supplementary Material). These data confirmed our in vitro 
observations that SW480 cells were resistant to cetuximab-
mediated growth inhibition (blue line). Of note, while treatment 
with UCB-NK cells alone significantly decreased the tumor load 
(green line), this effect was not increased by combining UCB-NK 
cells with cetuximab and thereby further confirmed both the 
FigUre 3 | significant antitumor effects of UcB-nK cells in vivo. Real-time monitoring of tumor progression and treatment response was performed 
measuring Gluc levels from mice blood twice a week. Baseline Gluc values were obtained from all mice a day before tumor injection (day 1), and further monitoring 
continued until day 35. Blood Gluc levels were compared between control SW480 only (A) group and treatment groups SW480 + cetuximab (B), SW480 + UCB-NK 
(C), and SW480 + UCB-NK + cetuximab (D) for statistical significance. Data presented is from six mice per group (n = 6). Scatter plots represent mean ± SEM. 
*P < 0.05, calculated with unpaired t test.
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inefficacy of cetuximab in treating RAS mutated tumors as 
well as the inability of cetuximab to induce ADCC of UCB-NK 
cells in  vivo (orange line) (Figure  3). CD16 expression levels 
on UCB-NK cells were monitored in two mice upon adoptive 
transfer and increased from 6.0% before transfer to 14.0% (mouse 
1) and 19.1% (mouse 2) at day 5 post UCB-NK cell infusion (data 
not shown).
While the blood Gluc assay measurements provided evidence 
of a reduction in the total tumor burden after UCB-NK treatment, 
we wanted to explore the impact of the therapy on the localization 
and size of the metastases. For that purpose, BLI was performed at 
day 35 after tumor inoculation. Figure 4A depicts four representa-
tive BLI images from each group at day 35 posttumor injection and 
average radiance from range of interest measurements are shown 
in Figure 4B. It is clear that mice from groups A and B showed 
a higher and more diffuse tumor load compared to mice treated 
with UCB-NK alone or in combination with cetuximab. In order 
to demonstrate the possibility of antitumor efficacy of cetuximab 
in the BRGS mouse model, we performed a similar tumor chal-
lenge using the cetuximab-sensitive A431 cell line, which bears 
wild-type RAS and overexpresses EGFR. A significant decrease 
in tumor load was observed when A431 tumors were treated 
with the same concentration of cetuximab as in the SW480 study 
(Figure 4C), confirming the in vivo functionality of cetuximab. 
We next assessed whether treatment of SW480 bearing mice with 
UCB-NK cells alone or in combination with cetuximab translated 
into a survival advantage (Figure 5). Indeed, treatment of mice 
with UCB-NK cells alone resulted in a significant prolongation in 
their life span (P = 0.01), whereas combinatorial therapy did not 
add significantly to this. Treatment with cetuximab alone did not 
translate into a significant survival advantage, consistent with the 
observed effects on tumor growth.
DiscUssiOn
In order to test the cytotoxic potential of NK cells for treating 
advanced CRC patients, we compared their functional status 
before and after chemotherapy. We observed that peripheral 
blood NK cell numbers were reduced in mCRC patients and 
that residual NK cells were dysfunctional and unable to mount a 
strong effector response when stimulated with an NK cell sensi-
tive tumor target. Though an increase in NK cell cytotoxicity was 
observed when tumor target cells were coated with the anti-EGFR 
mAb cetuximab, reflecting a capacity for ADCC, cytotoxicity was 
still significantly lower (both before and after chemotherapy) than 
that observed in healthy controls. These data indicate a decreased 
functional state of NK cells in patients with mCRC, which is in 
line with studies in mice where the cytokine production and 
antitumor activity of adoptively transferred NK cells were highly 
affected following long-term exposure to tumors (30). Through 
recognition of MHC class I molecules, KIRs prevent NK cells from 
targeting healthy cells while allowing them to detect tumor or 
FigUre 4 | continued
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FigUre 5 | significant survival benefit in cetuximab-resistant ras mutant tumor bearing mice treated with UcB-nK cells. Kaplan–Meier survival curves 
were plotted for the total experimental study period from day 0 until day 65. Survival rates of SW480 (EGFR+, RASmut) tumor-bearing mice (n = 6 per group) following 
treatment with PBS only (black line), cetuximab only (blue line), UCB-NK only (green line), and UCB-NK + cetuximab (orange line) were plotted over time to monitor 
treatment outcome. Statistical differences between groups were calculated using log-rank (Mantel–Cox) test and indicated in the figure.
FigUre 4 | continued 
successful tumor elimination by UcB-nK cells as revealed by bioluminescence imaging in vivo. (a) Four mice from control and treatment groups were 
imaged at day 35 for tumor load and distribution. Mice were injected retro-orbitally with Gluc substrate coelenterazine and images were acquired for 5 min. In 
SW480 control and SW480 + cetuximab groups, tumor growth was extensive and highly disseminated, spreading to most parts of the body. However, in UCB-NK 
and UCB-NK + cetuximab groups, there was a significantly lower tumor load, which was further verified by calculating the average radiance between groups as 
shown in panel (B) (n = 4 mice per group). (c) Cetuximab functionality against EGFR+++ RASwt A431 cells was tested in parallel to SW480 studies in BRGS mice 
(n = 3 mice per group). For panels (B,c), bars represent mean ± SEM. *P < 0.05 for panels (B,c) was calculated with unpaired t test.
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infected cells with low or downregulated expression of MHC class 
I in a process known as “missing self ” (31). Severely diminished 
or aberrant expression of MHC class I has been reported in the 
majority of colorectal adenocarcinomas (32, 33), which makes 
them an ideal target for NK cell-mediated killing. Although NK 
cells are infrequent in colorectal tissues (18), several independent 
studies investigated the clinical impact of NK cell infiltration on 
the prognosis of CRC, as well as in other types of carcinoma. These 
clinical studies, including a recent tissue microarray of 1,414 CRC 
biopsies, led to the conclusion that NK cell infiltration in tumors 
correlated with better overall response rates and progression-free 
survival in CRC patients (34–37), suggesting that therapies aimed 
at boosting NK cell functions could be beneficial in mCRC and 
possibly also in other types of cancer.
We evaluated and compared the cytotoxic efficacy of two dif-
ferent sources of feeder cell free allogeneic NK cells, i.e., A-PBNK 
cells and in vitro expanded and differentiated UCB-NK cells. In 
vitro NK cell cytotoxicity experiments revealed that the cytotoxic 
activity of UCB-NK cells against CRC cells was significantly 
higher than that of A-PBNK cells and in addition demonstrated 
that, while an increase in cytotoxicity through ADCC was not 
evident with UCB-NK cells, their cytotoxic potential was still 
comparable to that observed with A-PBNK potentiated by 
cetuximab-mediated ADCC. It is possible that the stronger 
cytotoxic effects of UCB-NK cells result from a more intense 
stimulation with cytokines in comparison to A-PBNK cells. The 
failure to observe ADCC-enhanced cytotoxicity with UCB-NK 
cells in vitro can be explained by their low expression levels of 
CD16 (29). As we previously observed in  vivo upregulation of 
CD16 on UCB-NK cells upon their transfer to NOD/SCID/
IL2Rgnull (NSG) mice (38), we decided to also test the efficacy 
of cetuximab treatment in combination with UCB-NK cells in an 
in vivo model. Treatment of SW480 RASmut tumors in BRGS mice 
with UCB-NK cells resulted in control of disease progression 
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and translated into a significantly longer survival. As expected, 
cetuximab monotherapy did not result in a decreased SW480 
tumor load or improvement in survival, recapitulating the clinical 
data from patients bearing RASmut CRC tumors. Unexpectedly, we 
failed to demonstrate superior in vivo antitumor effects or survival 
when we combined the transfer of UCB-NK cells with cetuximab 
infusions. The underlying causes for this latter finding remain 
obscure but may be related to suboptimal in vivo upregulation 
of CD16 in the used mouse model or CD16 polymorphisms in 
the employed batch of UCB-NK cells, both of which could have 
hampered efficient ADCC.
Taken together, UCB-NK cells displayed significant antitumor 
efficacy, suggesting a potential beneficial role for UCB-NK cells in 
the treatment of RAS and BRAF mutant CRC. As an important 
present limitation in treating mCRC patients is related to resist-
ance to anti-EGFR mAbs, adoptive transfer of cytolytic UCB-NK 
cells could thus constitute a viable treatment option. Our in vitro 
and in vivo data demonstrating that adoptive transfer of UCB-NK 
cells alone was as effective as the combination of A-PBNK and 
cetuximab raises the possibility that UCB-NK administration 
could obviate the use of cetuximab in RASwt mCRC. Furthermore, 
UCB-NK can also lyse RASmut CRC cells at levels higher than 
those observed with A-PBNK. Importantly, allogeneic NK cells 
have demonstrated their safety in clinical trials in several solid 
tumors (39, 40), and more specifically, the UCB-NK cell product 
used in our experiments was found to be safe in a clinical trial 
in acute myeloid leukemia (AML) patients (Dolstra et al., 2016 
manuscript submitted).
Several features make UCB-NK attractive for further clini-
cal development. For example, our GMP-based expansion and 
differentiation protocol reproducibly resulted in a more than 
10,000-fold expansion of cytotoxic UCB-NK cells from single 
donors. Furthermore, UCB-NK cells can be supplied as an “off 
the shelf ” product, stored in large aliquots facilitating multiple 
infusions. Also, the low immunogenicity by UCB grafts prevents 
adverse reactions that are prevalent after repeated PBNK transfu-
sions (41). In this respect, it is relevant to mention that while 
NK cells in general are often inhibited by recognition of MHC 
class I molecules on the surface of tumor cells, UCB-NK display 
relatively low levels of KIRs supporting their ability to effectively 
lyse MHC class I-expressing tumor cells (29). Finally, the ability 
of UCB-NK cells to proliferate and home to liver, lungs, spleen, 
and bone marrow after adoptive transfer has been previously 
demonstrated in NSG mice (38), though additional studies are 
required to determine whether UCB-NK cells have a similar 
migratory pattern upon adoptive transfer in solid tumor patients. 
Together, these features and observations provide UCB-NK cells 
with several unique advantages for further development as a 
universal NK cell platform.
Considering the size and heterogeneity of the tumor mass 
in advanced stages of CRC and other types of cancer, UCB-NK 
may not provide a sufficient therapeutic effect as a single agent. 
However, rational combinations of UCB-NK cells with existing 
drugs or drugs that are in clinical development can be envisioned 
to further increase their efficacy. Previous studies have pointed 
out that the proteasome inhibitor (bortezomib) (42) and the 
immunomodulatory drug (lenalidomide) (43) sensitize tumor 
cells to NK-mediated killing. In addition, UCB-NK cell applica-
tion together with bispecific or trispecific antibodies that bind to 
tumor and UCB-NK cell-activating receptors can also increase 
NK cell tumor specificity (44). Though we did not specifically 
assess ADCC induced by other mAbs, it is very likely that the 
failure of UCB-NK to mediate ADCC is a more general phe-
nomenon as this depends on binding to CD16/FcγRIII, which 
was found to be expressed at only low levels in the UCB-NK cell 
product. However, recent data from a clinical phase 1 study with 
the same UCB-NK cell product in patients with AML revealed 
significant upregulation of CD16 on UCB-NK cells post transfu-
sion suggesting that the UCB-NK cell product may acquire the 
capacity to mediate ADCC in patients following adoptive transfer 
(Dolstra et al., manuscript submitted). Further, this phenomenon 
may also provide a strong rationale for combining UCB-NK 
cells with bispecific or trispecific killer cell engagers (45). Taken 
together, these approaches can substantially increase UCB-NK 
cell responses to advanced solid tumors, including mCRC.
In conclusion, in this study, we have demonstrated the in vitro 
efficacy of UCB-NK cells against multiple CRC cell lines inde-
pendent of EGFR expression and EGFR downstream signaling 
mutations, and in addition have demonstrated the in vivo anti-
tumor efficacy of adoptively transferred UCB-NK cells against 
EGFR+RASmut tumors. As the adoptive transfer of UCB-NK cells 
(oNKord®) has been shown to be safe in patients with AML 
(CCMO no. NL31699 and Dutch trial register no 2818), our data 
provide a rationale for the clinical exploration of UCB-NK cells 
in the treatment of mCRC.
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